Suggestions
Andre Choulika Ph.D.
Chief Executive Officer
Andre Choulika Ph.D. is a prominent figure in the biotechnology industry, particularly in the field of gene editing and cancer immunotherapy. Here's a comprehensive overview of his professional background:
Professional Experience
Chief Executive Officer at Cellectis: Andre Choulika is the founder, Chairman, and CEO of Cellectis, a biopharmaceutical company he established in December 1999.1 Cellectis focuses on developing novel cancer therapies using engineered T-cells, particularly for treating leukemias and solid tumors.1
Board Member at Institut Pasteur: Since June 2019, Choulika has been serving as a Member of the Board of Directors at Institut Pasteur in Paris, France.1
Educational Background
Choulika's academic credentials include:
- Ph.D. in Molecular Virology from Université Pierre et Marie Curie (1985-1995)1
- Post-Doctoral Fellowship at Harvard Medical School, Department of Genetics and Molecular Medicine (1997-1999)1
- Management training from HEC School of Management (Challenge+ program, 2000-2001)1
Research and Expertise
Dr. Choulika is recognized for his work in genome engineering, particularly:
- Developing approaches for meganuclease-based human gene therapy while at Boston Children's Hospital1
- Expertise in TALEN™, meganucleases, and electroporation technology Pulsagile1
- Pioneering allogeneic T-cell chimeric antigen receptor (CAR) technology for cancer immunotherapy1
Industry Leadership
Beyond his role at Cellectis, Choulika has been actively involved in the biotechnology sector:
- Served as President of France Biotech, the French biotechnology association, for over four years1
- Contributes to the advancement of cell and gene therapy research2
Andre Choulika's work at Cellectis has been focused on developing innovative cancer treatments that aim to reduce toxicities associated with current chemotherapeutics and potentially offer curative therapies.1 His leadership has guided Cellectis in its mission to create a new generation of cancer immunotherapy, capitalizing on the company's extensive expertise in genome engineering.1
Highlights
Thank you Endpoints News for this article, I was moved by this teenager facing constant seizures and the story of this personalized drug developed just for him.
I’m wondering if we’re not getting closer to the end of the one-size-fits-all drugs. Afterall, we all have our own personalized genome, and our own life experience. We’re all peculiar patients and when we go to see a doctor we want to be seen as an individual.
Take a minute and think about a personalized drug, developed just for yourself. It sounds like the ultimate climax of drug development and a dream for any of us. How many people on earth, suffering from ultra-rare diseases, have dreamed of having their drug developed, just for themselves, as a cure?
Today with #genomics, #geneediting, #robotics, #DNA and #RNA design and synthesis, vector technologies, all of it powered by mighty algorithms (#AI), these dreams seem today within a reach.
We need the have the #biotech industry, #pharma companies but also the FDA, the EMA and other regulatory bodies to start rethinking the way to develop next generation drugs just for us and make it financially viable and possible for all patients with unmet medical needs.
Technologies are here, available, so let’s create the environment for this to happen. Too many patients are waiting and enduring their condition by themselves.
